You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Drug maker Onyx explores sale after rebuffing Amgen

NEW YORK — Onyx Pharmaceuticals Inc. said Sunday that it is weighing a sale of itself, after having rejected an unsolicited $10 billion takeover bid by Amgen Inc. last week as too low.

The company said in a statement that Amgen had proposed paying $120 a share in cash, a 38 percent premium to Onyx’s closing price on Friday. The biopharmaceutical drug maker said it has hired the investment bank Centerview Partners to contact possible suitors.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week